drug · protein

MOUNJARO

updated 2mo ago

/ tur-ZEP-ə-tyde /

by $LLY ELI LILLY & Co🔗 ChEMBL

community read0 votes

Protein drug with a maximum clinical stage of Approval (across all indications), with 6 approved and 8 investigational indications.

targets

Glucagon-like peptide 1 receptorGastric inhibitory polypeptide receptor

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

MOUNJARO

trade names

Mounjaro, Mounjaro (autoinjector), Zepbound, Zepbound (autoinjector)

generic

TIRZEPATIDE

MOA

12.1 Mechanism of Action Tirzepatide is a GIP receptor and GLP-1 receptor agonist. It contains a C20 fatty diacid that enables albumin binding and prolongs the half-life. Tirzepatide selectively binds to and activates both the GIP and GLP-1 receptors, the targets for native GIP and GLP-1. Tirzepatide enhances first- and second-phase insulin secretion, and reduces glucagon levels, both in a glucose-dependent manner.

indication

1 INDICATIONS AND USAGE MOUNJARO ® is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. MOUNJARO ® is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. ( 1 )

MOUNJARO

targets

all catalysts(0)

News(0)

Report a data issue

comments(0)

🐶 often sniffed alongside

Trials studying MOUNJARO